These results were confirmed using Method Two which identified reductions in MAPK signalling, cancer and the P53 pathway, JAK-STAT signalling, focal adhesion, lipid metabolism, and oxidative phosphorylation (Table M2S4). The gene discussed is TP53; the disease is cancer.